COMMUNIQUÉS West-GlobeNewswire

Informations sur le nombre total de droits de vote et d'actions
27/11/2024
INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 27 novembre 2024, 22:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 [...]
OneMedNet Announces Receipt of Nasdaq Notice Regarding Delayed Form 10-Q
27/11/2024
MINNEAPOLIS, Nov. 27, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World [...]
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia
27/11/2024
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced that the U.S. Food and [...]
Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq
27/11/2024
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today reported that it received a notice (the “5250 Notice”) on November 22, 2024 from the Listing Qualifications [...]
QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis
27/11/2024
QIAGEN introduces market’s first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applications and custom NGS panels // First-of-its-kind Custom Assay Design Tool [...]
Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference
27/11/2024
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients [...]
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
27/11/2024
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced [...]
Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates
27/11/2024
WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for [...]
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
27/11/2024
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr [...]
FSR Doubles Investment in Cardiac Sarcoidosis Research with $200,000 in Grants to Advance Diagnostic and Treatment Breakthroughs
27/11/2024
CHICAGO, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) is proud to announce the recipients of the 2024 FSR Cardiac Sarcoidosis Grant, providing $200,000 in funding to advance [...]
Enlitic and Laitek to Showcase Innovative AI Solutions at RSNA 2024
27/11/2024
Enlitic and Laitek Join Forces for the First Time Highlights Enlitic Acquired Laitek in October 2024 Enlitic and Laitek will showcase their innovative AI solutions at RSNA 2024 Enlitic (Booth 4365) will participate in [...]
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
27/11/2024
- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers – - ASXL1 Mutations Predictably Identified in Colorectal [...]
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area
27/11/2024
Webinar being held today "Evolving strategic context for phages, Introducing new opportunities" to present PHAXIAM Therapeutics strategy Based on the positive evolution in phages therapy market, PHAXIAM’s development [...]
PHAXIAM présente une stratégie de développement ambitieuse pour tirer parti de l'évolution rapide du marché de la phagothérapie
27/11/2024
Tenue d’un webinaire le 27 novembre 2024 « Evolving strategic context for phages, Introducing new opportunities » 1 pour présenter la stratégie de PHAXIAM Therapeutics Sur la base de l'évolution positive du marché de la [...]
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
27/11/2024
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect [...]
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
27/11/2024
BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyve™ from ProgenaCare Global WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB: [...]
Prenetics Announces Third Quarter 2024 Financial Results
27/11/2024
Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta’s Early Cancer Detection Reiterates [...]
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
27/11/2024
ARLINGTON, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare [...]
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
27/11/2024
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]

Pages